Nexus Pharmaceuticals, Inc.
175 E. Hawthorn Parkway
About Nexus Pharmaceuticals, Inc.At Nexus Pharmaceuticals, we are committed to making safe, quality generic drugs – and making sure they are accessible and affordable.
CEO: Mariam S. Darsot
CSO: Shahid Ahmed
Please click here for Nexus Pharma job opportunities.
17 articles with Nexus Pharmaceuticals, Inc.
Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥.
Nexus Pharmaceuticals Inc., a US-based healthcare company and domestic manufacturer, today announced that they transported via a special air freight charter through DB Schenker 82 tons of vaccine filling equipment, including a vaccine filling machine and isolator from Bausch + Stroebel and Franz Ziel.
Nexus Pharmaceuticals, Inc. is pleased to announce that it has received authorization to occupy its new pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin.
Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
Nexus Pharmaceuticals supports the Biden-Harris administration’s decision to invoke the Defense Production Act (DPA) in order to boost supplies needed for COVID-19 vaccine production and for at-home virus test kits.
Nexus Pharmaceuticals is pleased to announce their continuous certification as a Minority Business Enterprise (MBE) and a Women’s Business Enterprise (WBE).
Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™ ¥ . “Nexus Pharmaceuticals is very pleased to announce the approval of Succinylcholine Chloride. This critical need drug has seen an increased demand due to the COVID-19 pandemic and Nexus will be read
Nexus Pharmaceuticals, Inc. Announces Launch of Emerphed™ (ephedrine sulfate) RTU Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)
Nexus Pharmaceuticals announced today that it has launched its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial. With no need for compounding, diluting, or mixing, Emerphed saves valuable staff time while also reducing the potential for preparation error and waste. This press release features multimedia. View the full release here: https:/
Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10 mL vial)
Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin
Nexus Pharmaceuticals will invest $250 million to build U.S. based pharmaceutical facility bringing hundreds of new high-tech manufacturing jobs to Wisconsin
Immediate Availability of AP Rated Prochlorperazine Edisylate 10mg/2mL Injection
Launch of Dicyclomine HCl 20mg/2mL Injection- Now in a Vial
Nexus Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company's AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL).
Immediate Availability of 10mg per 10mL Vial of Generic Arsenic Trioxide for Intravenous Use
Nexus Pharma announced today the immediate availability in the United States of Procainamide HCL Injection, USP.